NATICK, Mass., Aug. 22, 2022 /PRNewswire/ — Avenge Bio, Inc., (“Avenge” or the “Company”) a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in…